Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001203209 | SCV001374361 | pathogenic | Epilepsy, childhood absence 2; Febrile seizures, familial, 8 | 2022-09-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 934755). This premature translational stop signal has been observed in individual(s) with clinical features of GABRG2-related conditions (PMID: 29778030). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg177*) in the GABRG2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GABRG2 are known to be pathogenic (PMID: 22539854, 22750526, 24407264). |
Gene |
RCV003129731 | SCV003805364 | pathogenic | not provided | 2023-02-14 | criteria provided, single submitter | clinical testing | Reported previously as a predicted deleterious variant in a child with intractable epilepsy (Hesse et al., 2018).; Not observed at significant frequency in large population cohorts (gnomAD); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 24407264, 23720301, 22750526, 22539854, 29778030, 35701389, 35627257) |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV003142129 | SCV003807819 | pathogenic | Developmental and epileptic encephalopathy, 74 | 2023-01-20 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1 very strong, PS4 supporting, PM2 moderated |